Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019

Professor Rob Jones introduces a session on the latest updates in the management of metastatic hormone sensitive prostate cancer (mHSPC) at ASCO 2019. He is joined by Professor Nick James, Professor Ian Davis and Dr Axel Merseburger.

Professor James provides an update on the STAMPEDE trial, Dr Merseburger provides an overview of the results of the TITAN trial and Professor Davis summarises the ENZAMET study presented at ASCO 2019. The experts discuss the distinguishing features of these studies and address the topic of sequential versus concurrent therapy for this patient group, debating whether data at ASCO has provided any evidence to support either therapeutic option.

The panel go on to discuss whether volume of disease impacts treatment response in patients with mHSPC and conclude the session by emphasising the importance of patient choice when selecting treatment for patients in this setting.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).